Skip to main content

Advertisement

SpringerLink
Log in

Endometrial cancer

  • Review
  • Published:
Cell and Tissue Research Aims and scope Submit manuscript

Abstract

Endometrial cancer is the most common gynaecological malignancy in the developed world. The majority of cases can be divided into two broad categories based on clinico-pathological and molecular characteristics; Type I oestrogen-dependent with endometrioid morphology and Type II non-oestrogen-dependent with serous papillary or clear cell morphology. As has been described for other malignancies, such as colorectal carcinoma, the transition from normal endometrium to carcinoma is thought to involve a stepwise accumulation of alterations in cellular regulatory pathways leading to dysfunctional cell growth. This article reviews the current knowledge of the molecular changes commonly associated with endometrial cancer and presents possible progression models.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F (1995) Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 86:479–485

    PubMed  Google Scholar 

  • Arnett-Mansfield RL, deFazio A, Wain GV, Jaworski RC, Byth K, Mote PA, Clarke CL (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61:4576–4582

    PubMed  Google Scholar 

  • Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17

    Article  PubMed  Google Scholar 

  • Breivik J, Gaudernack G (1999) Genomic instability, DNA methylation, and natural selection in colorectal carcinogenesis. Semin Cancer Biol 9:245–254

    Article  PubMed  Google Scholar 

  • Bryant W, Snowhite AE, Rice LW, Shupnik MA (2004) The estrogen receptor-{alpha} (ER{alpha}) variant {Delta}5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells. Endocrinology 146:751-759

    Article  PubMed  Google Scholar 

  • Bullions LC, Levine AJ (1998) The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 10:81–87

    PubMed  Google Scholar 

  • Catasus L, Matias-Guiu X, Machin P, Zannoni GF, Scambia G, Benedetti-Panici P, Prat J (2000) Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability. Cancer 88:2290–2297

    Article  PubMed  Google Scholar 

  • Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP, Saunders PT (2002) Wild-type estrogen receptor (ERbeta1) and the splice variant (ERbetacx/beta2) are both expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 87:5265–5273

    Article  PubMed  Google Scholar 

  • De Vivo I, Huggins GS, Hankinson SE, Lescault PJ, Boezen M, Colditz GA, Hunter DJ (2002) A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci USA 99:12263–12268

    Article  PubMed  Google Scholar 

  • Doldi N, Bassan M, Gulisano M, Broccoli V, Boncinelli E, Ferrari A (1996) Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol Endocrinol 10:375–382

    PubMed  Google Scholar 

  • Dougall WC, Qian X, Peterson NC, Miller MJ, Samanta A, Greene MI (1994) The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene 9:2109–2123

    PubMed  Google Scholar 

  • Dunlop MG, Farrington SM, Carothers AD, Wyllie AH, Sharp L, Burn J, Liu B, Kinzler KW, Vogelstein B (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6:105–110

    Article  PubMed  Google Scholar 

  • Enomoto T, Inoue M, Perantoni AO, Buzard GS, Miki H, Tanizawa O, Rice JM (1991) K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 51:5308–5314

    PubMed  Google Scholar 

  • Erkanli S, Eren F, Pekin S, Bagis T (2004) BCL-2 and P53 expression in endometrial carcinoma. J Exp Clin Cancer Res 23:97–103

    PubMed  Google Scholar 

  • Fukuchi T, Sakamoto M, Tsuda H, Maruyama K, Nozawa S, Hirohashi S (1998) Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58:3526–3528

    PubMed  Google Scholar 

  • Geisler JP, Geisler HE, Manahan KJ, Miller GA, Wiemann MC, Zhou Z, Crabtree W (2004) Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and relationship to survival. Int J Gynecol Cancer 14:133–137

    Article  PubMed  Google Scholar 

  • Giatromanolaki A, Sivridis E, Koukourakis MI, Harris AL, Gatter KC (1998) Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Res 18:3689–3693

    PubMed  Google Scholar 

  • Gurin CC, Federici MG, Kang L, Boyd J (1999) Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res 59:462–466

    PubMed  Google Scholar 

  • Herynk MH, Fuqua SA (2004) Estrogen receptor mutations in human disease. Endocr Rev 25:869-898

    Article  PubMed  Google Scholar 

  • Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T (2001) Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 80:181–188

    Article  PubMed  Google Scholar 

  • Holland CM, Day K, Evans A, Smith SK (2003) Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 89:891–898

    Article  PubMed  Google Scholar 

  • Horikawa I, Barrett JC (2003) Transcriptional regulation of the telomerase hTERT gene as a target cellular and viral oncogenic mechanisms. Carcinogenesis 24:1167–1176

    Article  PubMed  Google Scholar 

  • Horvath G, Leser G, Hahlin M, Henriksson M (2000) Exon deletions and variants of human estrogen receptor mRNA in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer 10:128–136

    PubMed  Google Scholar 

  • Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW (2001) Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed Mullerian tumors have altered ER and PR isoform expression. Oncogene 20:6965–6969

    Article  PubMed  Google Scholar 

  • Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Morgan E, Yang JJ, Yordan EL (1996) Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Am J Obstet Gynecol 174:1879–188 (discussion 1882–1884)

    Article  PubMed  Google Scholar 

  • Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW (2000) Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Path 13:379–388

    Article  Google Scholar 

  • Lagarda H, Catasus L, Arguelles R, Matias-Guiu X, Prat J (2001) K-ras mutations in endometrial carcinomas with microsatellite instability. J Pathol 193:193–199

    Article  PubMed  Google Scholar 

  • Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59–65

    PubMed  Google Scholar 

  • Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814–824

    Article  PubMed  Google Scholar 

  • Lecce G, Meduri G, Ancelin M, Bergeron C, Perrot-Applanat M (2001) Presence of estrogen receptor beta in the human endometrium through the cycle: expression in glandular, stromal, and vascular cells. J Clin Endocrinol Metab 86:1379–1386

    Article  PubMed  Google Scholar 

  • Levine RL, Cargile CB, Blazes MS, Rees B van, Kurman RJ, Ellenson LH (1998) PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 58:3254–3258

    PubMed  Google Scholar 

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947

    Article  PubMed  Google Scholar 

  • Machin P, Catasus L, Pons C, Munoz J, Matias-Guiu X, Prat J (2002) CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Human Pathol 33:206–212

    Article  Google Scholar 

  • Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, Berchuck A, Futreal PA (1998) Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 58:2500–2503

    PubMed  Google Scholar 

  • Mirabelli-Primdahl L, Gryfe R, Kim H, Millar A, Luceri C, Dale D, Holowaty E, Bapat B, Gallinger S, Redston M (1999) Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway. Cancer Res 59:3346–3351

    PubMed  Google Scholar 

  • Moll UM, Chalas E, Auguste M, Meaney D, Chumas J (1996) Uterine papillary serous carcinoma evolves via a p53-driven pathway. Human Pathol 27:1295–1300

    Article  Google Scholar 

  • Moreno-Bueno G, Hardisson D, Sanchez C, Sarrio D, Cassia R, Garcia-Rostan G, Prat J, Guo M, Herman JG, Matias-Guiu X, Esteller M, Palacios J (2002) Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21:7981–7990

    Article  PubMed  Google Scholar 

  • Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C (2000) Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92:924–930

    Article  PubMed  Google Scholar 

  • Niederacher D, An HX, Cho YJ, Hantschmann P, Bender HG, Beckmann MW (1999) Mutations and amplification of oncogenes in endometrial cancer. Oncology 56:59–65

    PubMed  Google Scholar 

  • Oehler MK, Rees MC, Bicknell R (2000) Steroids and the endometrium. Curr Med Chem 7:543–560

    PubMed  Google Scholar 

  • Oehler MK, Hague S, Rees MC, Bicknell R (2002) Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 21:2815–2821

    Article  PubMed  Google Scholar 

  • Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505–3512

    PubMed  Google Scholar 

  • Parc YR, Halling KC, Burgart LJ, McDonnell SK, Schaid DJ, Thibodeau SN, Halling AC (2000) Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology. Int J Cancer 86:60–66

    Article  PubMed  Google Scholar 

  • Prat J, Oliva E, Lerma E, Vaquero M, Matias-Guiu X (1994) Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 74:1778–1783

    PubMed  Google Scholar 

  • Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736–4738

    PubMed  Google Scholar 

  • Risinger JI, Maxwell GL, Berchuck A, Barrett JC (2003) Promoter hypermethylation as an epigenetic component in Type I and Type II endometrial cancers. Ann N Y Acad Sci 983:208–212

    PubMed  Google Scholar 

  • Saegusa M, Okayasu I (2000) Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium. Jpn J Cancer Res 91:510–518

    PubMed  Google Scholar 

  • Saegusa M, Hashimura M, Yoshida T, Okayasu I (2001) Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 84:209–217

    Article  PubMed  Google Scholar 

  • Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55:5693–5698

    PubMed  Google Scholar 

  • Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M (2002) Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 62:4849–4853

    PubMed  Google Scholar 

  • Salvesen HB, MacDonald N, Ryan A, Iversen OE, Jacobs IJ, Akslen LA, Das S (2000) Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 6:3607–3613

    PubMed  Google Scholar 

  • Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, Macdonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S (2004) Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25:1615–1623

    PubMed  Google Scholar 

  • Santin AD, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman JJ, Hutchins L, Pecorelli S, O’Brien T, Cannon MJ, Parham GP (2002) Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 8:1271–1279

    Google Scholar 

  • Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A, et al (1993) Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53:1906–1910

    PubMed  Google Scholar 

  • Sasaki M, Kotcherguina L, Dharia A, Fujimoto S, Dahiya R (2001) Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res 61:3262–3266

    PubMed  Google Scholar 

  • Schlosshauer PW, Ellenson LH, Soslow RA (2002) Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Path 15:1032–1037

    Article  Google Scholar 

  • Scholten AN, Creutzberg CL, Broek LJ van den, Noordijk EM, Smit VT (2003) Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma. J Pathol 201:460–465

    Article  PubMed  Google Scholar 

  • Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI (2002) Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 95:1055–1063

    PubMed  Google Scholar 

  • Skrzypczak M, Bieche I, Szymczak S, Tozlu S, Lewandowski S, Girault I, Radwanska K, Szczylik C, Jakowicki JA, Lidereau R, Kaczmarek L (2004) Evaluation of mRNA expression of estrogen receptor beta and its isoforms in human normal and neoplastic endometrium. Int J Cancer 110:783–787

    Article  PubMed  Google Scholar 

  • Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH (2004) Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22:3126–3132

    Article  PubMed  Google Scholar 

  • Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15:356–362

    PubMed  Google Scholar 

  • Takai N, Ueda T, Nishida M, Nasu K, Miyakawa I (2004) The relationship between oncogene expression and clinical outcome in endometrial carcinoma. Curr Cancer Drug Targets 4:511–520

    PubMed  Google Scholar 

  • Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L (1997a) p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150:177–185

    PubMed  Google Scholar 

  • Tashiro H, Lax SF, Gaudin PB, Isacson C, Cho KR, Hedrick L (1997b) Microsatellite instability is uncommon in uterine serous carcinoma. Am J Pathol 150:75–79

    PubMed  Google Scholar 

  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532

    PubMed  Google Scholar 

  • Wang Z, Kyo S, Maida Y, Takakura M, Tanaka M, Yatabe N, Kanaya T, Nakamura M, Koike K, Hisamoto K, Ohmichi M, Inoue M (2002) Tamoxifen regulates human telomerase reverse transcriptase (hTERT) gene expression differently in breast and endometrial cancer cells. Oncogene 21:3517–3524

    PubMed  Google Scholar 

  • Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT (1994) The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 96:516–520

    Article  PubMed  Google Scholar 

  • Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, Warner M, Gustafsson JA (2000) Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 97:5936–5941

    Article  PubMed  Google Scholar 

  • Williams JA Jr, Wang ZR, Parrish RS, Hazlett LJ, Smith ST, Young SR (1999) Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer. Exp Mol Pathol 67:135–143

    Article  PubMed  Google Scholar 

  • Yin Y, Solomon G, Deng C, Barrett JC (1999) Differential regulation of p21 by p53 and Rb in cellular response to oxidative stress. Mol Carcinog 24:15–24

    Article  PubMed  Google Scholar 

  • Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Sakamoto A, Sakamoto T, Maruyama H, Sato S, Mizunuma H, Smith SK (2003) Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin Cancer Res 9:1361–1369

    PubMed  Google Scholar 

  • Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA (1996) p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 61:167–174

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anatomical Pathology, Monash Medical Centre, Clayton, Victoria, Australia

    Andrew J. Ryan & Beatrice Susil

  2. Department of Gynaecological Oncology, Monash Medical Centre, PO Box 72, East Bentleigh, Victoria, 3165, Australia

    Thomas W. Jobling & Martin K. Oehler

Authors
  1. Andrew J. Ryan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Beatrice Susil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas W. Jobling
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin K. Oehler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin K. Oehler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ryan, A.J., Susil, B., Jobling, T.W. et al. Endometrial cancer. Cell Tissue Res 322, 53–61 (2005). https://doi.org/10.1007/s00441-005-1109-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00441-005-1109-5

Keywords

Search

Navigation